Kanaan Sellers Group Prepares for Nasdaq Nordic Listing
2.6.2025 08:00:00 CEST | Business Wire | Press Release
Kanaan Sellers Group (“Kanaan”), a leading European eCommerce aggregator focused on kitchen, home, and outdoor living brands, announces its intention to go public on the Nasdaq First North Premier Growth Market later this year, targeting a valuation around Euro 40mn in early Q4.
Founded by former Goldman Sachs Director Mike Vermeulen, Kanaan has built a robust and profitable business model in a challenging eCommerce environment. In an industry that has seen significant transformation including consolidation and shifts in strategies among aggregators, Kanaan has achieved profitable, sustainable growth by acquiring, operating, and scaling high-margin, niche consumer brands. Kanaan’s focused and capital-efficient approach – favouring equity financing over venture debt for its initial acquisition phase – has proven to be a winning strategy.
Backed by Infinitas Capital, a next-gen single-family office led by Robin Lauber, Kanaan has grown to manage 12 brands across nine European markets, generating seven figure EBITDA in 2024. Kanaan runs a well-diversified product portfolio with over 400 SKUs sold across all major platforms – including Amazon, Otto and Galaxus – while its proprietary direct-to-consumer channels are driving growth and customer engagement. Kanaan has plans to expand beyond Europe into the UK and the US.
Mike Vermeulen, CEO and Co-Founder of Kanaan Sellers Group, said:
“Over the past three years, we have built a business that not only withstands a challenging market but does so profitably. In a frequently maligned sector, we have emerged as a standout performer. What sets us apart is our disciplined approach to capital allocation and acquisitions, even during market highs; best-in-class working capital financing; and an experienced team of professionals in finance, supply chain, and e-commerce. This is an opportune moment in the market, where high quality brands are available at extremely attractive valuations, and we have a proven business model to scale them.
“A Nasdaq Nordic listing would reflect both the strength of our European operations and the appeal of the region’s diverse and engaged investors. It marks the next step in our growth and will provide a strong capital base to accelerate expansion.”
Kanaan’s agile and opportunistic approach capitalises on the unique post-pandemic window of opportunity. This ability to act quickly in a buyer’s market has allowed Kanaan to acquire quality, founder-led brands at compelling valuations.
Kanaan’s flagship brand, Springlane, demonstrates the company’s value creation strategy. A multi-category kitchen brand active in six countries, Springlane continues to contribute substantially towards overall revenues. It is a true multi-channel business, and direct-to-consumer channels are supported by original content and a loyal customer base. It is a case in point of Kanaan’s ability to scale and integrate acquisitions, and serves as a repeatable blueprint for future growth.
The proposed IPO will provide growth capital and increased market visibility, strengthening Kanaan’s ability to acquire and partner with founder-led business. As the global eCommerce retail market continues its upward trajectory, expected to reach $6.5 trillion by 2028, Kanaan is uniquely positioned to lead value-driven consolidation across a fragmented and undervalued sector.
Robin Lauber, Founder of Infinitas Capital, commented:
“We are extremely proud to support Kanaan Sellers Group as they continue to demonstrate their ability to create lasting value. Mike and the team have built a profitable growth engine, driven by a clear strategy of identifying value, executing quickly, and integrating effectively. As they prepare to enter the public markets, we look forward to their continued success as they lead the next wave of eCommerce consolidation.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250601404228/en/
Contacts
For more information, visit https://kanaan.ch/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fkanaan.ch%2F&e
sheet=54262621&newsitemid=20250601404228&lan=en-US&anchor=https%3A%2F%2Fkanaan.c
h%2F&index=1&md5=862c35c13562068a647691155f83dcf0 or contact:
Rosewood
Email: media@infinitas-capital.com
Phone: +44 (0)20 7653 8702
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom